WORCESTER, Mass., May 26, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that a presentation was made regarding the vaccine platform being developed by its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentation, describing the potential for increased antibody stimulation using the Antigen Express novel vaccines, was made at the BIT Life Sciences’ 1st Annual International Congress of Antibodies held in Beijing, China, May 22-24, 2009 (www.bitlifesciences.com/ica2009/).
